Lifecore Biomedical, Inc. (LFCR) stock forecast & analysis
6.36
NasdaqGS · USDDelayed by 15 minutes
Down: -0.04, -0.6%
6.36Down: +0.00, -0.1%
2 analyses
- Open
- 6.38
- Previous close
- 6.40
- Day range
- 6.36 – 6.39
- 52-week range
- 3.63 – 8.98
- Volume (shares)
- 780.49K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 37.91M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.97
- Market cap
- 241.08M
Market Scanner’s AI analysis of Lifecore Biomedical, Inc. (LFCR), updated October 2026: Lifecore Biomedical's acquisition by Webster Equity Partners and recent analyst downgrades were key themes in recent coverage.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Lifecore Biomedical, Inc. (LFCR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Lifecore Biomedical's acquisition by Webster Equity Partners and recent analyst downgrades were key themes in recent coverage.
Recent analyses for LFCR covered a strong technical uptrend indicated by moving averages and momentum indicators, alongside significant financial headwinds including net losses and negative shareholder equity. News coverage highlighted multiple analyst downgrades from Outperform/Buy to Market Perform/Hold, while also noting the announcement of an acquisition by Webster Equity Partners.
LFCR news & sentiment
News coverage indicated a bearish sentiment with multiple analyst downgrades. However, a major corporate event was the announcement of Lifecore Biomedical's acquisition by Webster Equity Partners.
LFCR technical picture
LFCR's price action showed a strong uptrend, trading significantly above its 50-day and 200-day SMAs. Momentum indicators like RSI and MACD suggested upward momentum, with RSI entering overbought territory, while MFI indicated positive buying pressure.
Fundamentals
Revenue has fluctuated, with the most recent quarter showing an increase from the prior quarter, though the company has reported significant net losses and negative cash flow from operations. Shareholder equity has deteriorated, becoming negative in the latest reporting period.
Factors discussed — upside
- Price trading significantly above 50-day and 200-day SMAs.
- Strong momentum indicated by RSI and MACD.
- Extension of manufacturing contract with Alcon Research.
- Announcement of acquisition by Webster Equity Partners for up to $663 million.
Factors discussed — risks
- Net loss reported for the quarter ending June 30, 2026.
- Negative shareholder equity as of June 30, 2026.
- Negative cash flow from operations in recent periods.
- Multiple analyst downgrades from Outperform/Buy to Market Perform/Hold.
- Technical indicators
- Financial performance
- Analyst sentiment
- Mergers and acquisitions
Summary updated .
LFCR technical indicators
Common technical indicators for LFCR, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 5.60 | Price above |
| 10-day exponential moving average | 6.41 | Price below |
| Relative strength index (14-day) | 60.30 | Neutral |
| MACD line (12/26/9) | 0.1777 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 6.33 – 6.50 | Price inside the bands |
Frequently asked questions
- What is the bull case for Lifecore Biomedical, Inc.?
- The bull case for LFCR centers on its strong technical uptrend, evidenced by prices significantly outperforming moving averages and robust momentum indicators. Continued business relationships, such as the manufacturing contract extension with Alcon Research, and the announced acquisition by Webster Equity Partners for up to $663 million, were also noted as positive developments.
- What are the risks for Lifecore Biomedical, Inc.?
- Risks for LFCR discussed in the analyses include a reported net loss for the most recent quarter, negative shareholder equity as of June 30, 2026, and negative cash flow from operations in recent periods. Additionally, multiple analyst downgrades from Outperform/Buy to Market Perform/Hold suggest increasing caution regarding the company's future performance or valuation.
- Is Lifecore Biomedical, Inc. bullish or bearish?
- Recent AI analyses of Lifecore Biomedical, Inc. examined factors on both sides. Discussed upside: The bull case for LFCR centers on its strong technical uptrend, evidenced by prices significantly outperforming moving averages and robust momentum indicators. Continued business relationships, such as the manufacturing contract extension with Alcon Research, and the announced acquisition by Webster Equity Partners for up to $663 million, were also noted as positive developments. Discussed risks: Risks for LFCR discussed in the analyses include a reported net loss for the most recent quarter, negative shareholder equity as of June 30, 2026, and negative cash flow from operations in recent periods. Additionally, multiple analyst downgrades from Outperform/Buy to Market Perform/Hold suggest increasing caution regarding the company's future performance or valuation. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lifecore Biomedical, Inc.?
- News coverage indicated a bearish sentiment with multiple analyst downgrades. However, a major corporate event was the announcement of Lifecore Biomedical's acquisition by Webster Equity Partners.
- How does Market Scanner analyse Lifecore Biomedical, Inc.?
- Every analysis of Lifecore Biomedical, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Lifecore Biomedical, Inc.?
The bull case for LFCR centers on its strong technical uptrend, evidenced by prices significantly outperforming moving averages and robust momentum indicators. Continued business relationships, such as the manufacturing contract extension with Alcon Research, and the announced acquisition by Webster Equity Partners for up to $663 million, were also noted as positive developments.
What are the risks for Lifecore Biomedical, Inc.?
Risks for LFCR discussed in the analyses include a reported net loss for the most recent quarter, negative shareholder equity as of June 30, 2026, and negative cash flow from operations in recent periods. Additionally, multiple analyst downgrades from Outperform/Buy to Market Perform/Hold suggest increasing caution regarding the company's future performance or valuation.
Is Lifecore Biomedical, Inc. bullish or bearish?
Recent AI analyses of Lifecore Biomedical, Inc. examined factors on both sides. Discussed upside: The bull case for LFCR centers on its strong technical uptrend, evidenced by prices significantly outperforming moving averages and robust momentum indicators. Continued business relationships, such as the manufacturing contract extension with Alcon Research, and the announced acquisition by Webster Equity Partners for up to $663 million, were also noted as positive developments. Discussed risks: Risks for LFCR discussed in the analyses include a reported net loss for the most recent quarter, negative shareholder equity as of June 30, 2026, and negative cash flow from operations in recent periods. Additionally, multiple analyst downgrades from Outperform/Buy to Market Perform/Hold suggest increasing caution regarding the company's future performance or valuation. These are descriptive observations, not a recommendation.
What is the latest sentiment on Lifecore Biomedical, Inc.?
News coverage indicated a bearish sentiment with multiple analyst downgrades. However, a major corporate event was the announcement of Lifecore Biomedical's acquisition by Webster Equity Partners.
How does Market Scanner analyse Lifecore Biomedical, Inc.?
Every analysis of Lifecore Biomedical, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh LFCR.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.